Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment by Seitz, Christoph et al.
ORIGINAL RESEARCH
published: 28 August 2019
doi: 10.3389/fonc.2019.00805
Frontiers in Oncology | www.frontiersin.org 1 August 2019 | Volume 9 | Article 805
Edited by:
Jin S. Im,
University of Texas MD Anderson
Cancer Center, United States
Reviewed by:
Irena Adkins,
SOTIO a.s., Czechia
Amorette Barber,
Longwood University, United States
*Correspondence:
Udo S. Gaipl
udo.gaipl@uk-erlangen.de
†These authors have contributed
equally to this work as first authors
‡These authors have contributed
equally to this work as senior authors
Specialty section:
This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Oncology
Received: 31 January 2019
Accepted: 07 August 2019
Published: 28 August 2019
Citation:
Seitz C, Rückert M, Deloch L,
Weiss E-M, Utz S, Izydor M, Ebel N,
Schlücker E, Fietkau R, Gaipl US and
Frey B (2019) Tumor Cell-Based
Vaccine Generated With High
Hydrostatic Pressure Synergizes With
Radiotherapy by Generating a
Favorable Anti-tumor Immune
Microenvironment.
Front. Oncol. 9:805.
doi: 10.3389/fonc.2019.00805
Tumor Cell-Based Vaccine Generated
With High Hydrostatic Pressure
Synergizes With Radiotherapy by
Generating a Favorable Anti-tumor
Immune Microenvironment
Christoph Seitz 1†, Michael Rückert 1†, Lisa Deloch 1, Eva-Maria Weiss 1,2, Sebastian Utz 1,
Marika Izydor 3, Nina Ebel 4, Eberhard Schlücker 3, Rainer Fietkau 1, Udo S. Gaipl 1*‡ and
Benjamin Frey 1‡
1Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen,
Erlangen, Germany, 2Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg,
Universitätsklinikum Erlangen, Erlangen, Germany, 3 Institute of Process Machinery and Systems Engineering,
Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 4Department of Cardiac Surgery,
Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany
Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure
(HHP)-inactivated tumor cells have been demonstrated to be a promising immunotherapy
for solid tumors. We focused on sole injection of tumor cells that were inactivated by
HHP and their combination with local radiotherapy (RTx) for in vivo induction of
anti-tumor immune responses. HHP-treatment of tumor cells resulted in pre-dominantly
necrotic cells with degraded DNA. We confirmed that treatments at 200 MPa or higher
completely inhibited the formation of tumor cell colonies in vitro. No tumor growth was
seen in vivo after injection of HHP-treated tumor cells. Single vaccination with HHP-killed
tumor cells combined with local RTx significantly retarded tumor growth and improved
the survival as shown in B16-F10 and CT26 tumor models. In B16-F10 tumors that
were irradiated with 2 × 5Gy and vaccinated once with HHP-killed tumor cells, the
amount of natural killer (NK) cells, monocytes/macrophages, CD4+ T cells and NKT
cells was significantly increased, while the amount of B cells was significantly decreased.
In both models, a trend of increased CD8+ T cell infiltration was observed. Generally,
in irradiated tumors high amounts of CD4+ and CD8+ T cells expressing PD-1 were
found. We conclude that HHP generates inactivated tumor cells that can be used as a
tumor vaccine. Moreover, we show for the first time that tumor cell-based vaccine acts
synergistically with RTx to significantly retard tumor growth by generating a favorable
anti-tumor immune microenvironment.
Keywords: radiotherapy, immunotherapy, tumor cell-based vaccine, high hydrostatic pressure, malignant
melanoma, colorectal carcinoma, tumor-infiltrating leukocytes, tumor microenvironment
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INTRODUCTION
In recent years, cancer immunotherapy has revived. It comes
in a variety of forms, including checkpoint inhibitors, targeted
antibodies, adoptive cell transfer, tumor-infecting viruses,
cytokines, adjuvants, and cancer vaccines. Cancer vaccines aim
specifically to activate the immune system in cancer patients
(1). As dendritic cells (DCs) link the innate and adaptive
immune system as powerful antigen-presenting cells, they were
used as cancer vaccines in several clinical trials. DC-based
immunotherapy has been demonstrated to be safe and capable of
inducing anti-tumor immunity. Long-term survival in advanced
melanoma patients undergoing DC vaccination is similar to
ipilimumab-treated patients (2). Nevertheless, the response rates
are often low. Improved vaccines with higher immunogenicity
and particularly combination with other tumor therapies should
therefore be implemented (3).
High hydrostatic pressure (HHP)-treatment is an innovative
method for the generation of whole cell-based tumor vaccines.
Although HHP has been mainly used in the food industry
for processing and preserving meat and other food to avoid
thermal treatment (4). Though HHP is known to denature
proteins, it doesn’t affect covalent bonds, meaning that the
proteins’ primary and secondary structure is maintained, whereas
their tertiary and quaternary structure is changed (5). Urbanova
et al. showed that HHP-treatment of tumor cells affects the
antigenic pool and that loading of DCs with HHP-killed tumor
cells can induce CD8+ T cell responses in vitro (6). Fucikova
et al. demonstrated that HHP-treatment induces immunogenic
cancer cell death in human tumor cells and that interaction
of HHP-killed cancer cells with DCs results in phagocytosis
of the tumor cells and activation of the DCs (7). DCs
pulsed with HHP-killed cancer calls can be used as cancer
vaccine (8). Based on these data, ex vivo HHP-killed tumor
cell-loaded DCs are currently being tested in clinical trials
as therapeutic cancer vaccines. For this, patient’s monocyte-
derived DCs pulsed with HHP-killed allogeneic tumor cell
lines (DCVAC) are used to treat prostate, ovarian and lung
cancer (NCT03514836, NCT03905902, NCT02470468). One
has to stress that such tumor vaccination is well-combinable
with chemotherapy (9).
We have aimed to test whether sole injection of HHP-killed
tumor cells without DCs can also be used as a cancer vaccine
in a multimodal approach together with RTx, hypothesizing
that under distinct in vivo micro-environmental conditions
such inactivated tumor cells are taken up by endogenous DCs.
We already demonstrated in previous work that murine CT26
tumor cells are effectively inactivated by HHP-treatment and
that specific IgG antibodies against tumor cells were significantly
Abbreviations: AnxA5, AnnexinA5; CTLA-4, cytotoxic T-lymphocyte-associated
Protein 4; DC, dendritic cell; FELASA, Federation of European Laboratory Animal
Science Associations; GM-CSF, granulocyte-macrophage colony-stimulating
factor; GV-SOLAS, Gesellschaft für Versuchstierkunde; HHP, high hydrostatic
pressure; HLA, human leukocyte antigen; NK, natural killer; PI, propidium
iodide; PD-1, programmed cell death protein 1; RTx, radiotherapy; SD, standard
deviation; SEM, standard error of the mean; TAA, tumor-associated antigen; TIL,
tumor-infiltrating leukocytes.
increased after immunization of mice with HHP-treated tumor
cells (10). This work gave first hints that sole injection of HHP-
killed tumor cells is capable of triggering anti-tumor immune
responses in vivo. In variance to the approach of DC pulsed
vaccines, we use syngeneic rather than allogeneic tumor cells for
vaccination. This syngeneic vaccine mimicking in cancer patients
autologous vaccine from their own tumor cells should contain
all potentially relevant tumor-associated antigens (TAAs) for a
particular patient (11).
It should be stressed that HHP treatment fulfills the main
requirements for clinical vaccine: it effectively inactivates tumor
cells, it has no intrinsic toxicity, it does not destroy the
immunogenicity of the tumor cells and it can be applied with legal
and GMP-compliant requirements. Further, it is further a highly
reproducible and easy to apply method (12). Therefore, HHP is
advantageous to other preparation methods such as heat killing,
radiation, or freeze-thaw approaches.
We performed our pre-clinical studies with two broadly
used B16-F10 melanoma and CT26 colorectal cancer models.
Although malignant melanoma is an aggressive disease with
rising incidence and high resistance to classical therapy, targeted
therapies and immune therapy have significantly improved
the treatment of patients with advanced malignant melanoma
in recent years (13). In colorectal cancer, the proportion of
patients with an immunosuppressive tumor microenvironment
is high, again calling for combination therapies that modulate the
immune system (14).
Emerging evidence suggests that radiotherapy (RTx) is
capable of activating the patient’s immune system by acting as an
in situ cancer vaccine (15, 16). RTx modifies the phenotype of the
tumor cells and the tumor microenvironment (17). It however
results in both, immune activation and immune suppression (18).
Therefore, the combination of RTx with immunotherapy has the
potential to induce regression of tumors, even outside of the
radiation field (19).
It has become evident that in established cancers anti-
tumor vaccines will require co-treatments to overcome immune
evasion (20). RTx might act as adjuvants for the vaccine and
this combination might be effective in generating anti-tumor
immune responses. Here we show for the first time that a
single vaccination with HHP-killed tumor cells combined with
local RTx significantly retards tumor growth and improves
survival of tumor-bearing mice by generating a favorable anti-
tumor immune environment as analyzed in B16-F10 and CT26
tumor models.
MATERIALS AND METHODS
Cell Lines and Cell Culture
B16-F10 melanoma and CT26 colon carcinoma cells were both
obtained fromATCC (Manassas, VA, USA). The tumor cells were
grown up to amaximum confluence of 80% at 37◦C, 5%CO2, and
95% humidity, in RPMI 1640 (Sigma Aldrich,Munich, Germany)
with the addition of 10 % fetal bovine serum (FBS, Biochrom
AG, Berlin, Germany) and 1% penicillin-streptomycin (PenStrep,
Gibco, Carlsbad, USA).
Frontiers in Oncology | www.frontiersin.org 2 August 2019 | Volume 9 | Article 805
Seitz et al. HHP Vaccine Suits to Radiotherapy
High Hydrostatic Pressure Treatment
After detaching of the adherent tumor cells, the cell suspension
was transferred into cryovials (Greiner Bio-one, Frickenhausen,
Germany). The vials were filled completely (2.5ml) and closed
tightly by avoiding any air bubbles. Afterwards the vials were
sealed with ParafilmTM (American National Can, Chicago, USA)
to prevent leaking.
The equipment for HHP-treatment (Supplemental Figure 1)
was provided by the “Institut für Prozessmaschinen und
Anlagentechnik” (iPAT, Friedrich-Alexander-Universität
Erlangen-Nürnberg). For pressurizing the tumor cells, the
cryovial with the cell suspension was put into the autoclave (1).
Pressure that was built up at a velocity of around 5 MPa/s by
a manual spindle press (2) in addition to a pneumatic pump
(3) was transmitted to the autoclave via a system of metal
tubes (4) containing pressure transmitting fluid (hydraulic oil
Ultra-Safe 620, Petrofer, Hildesheim, Germany). According to
Pascal’s law, pressure which is generated and transmitted by
the transmitting fluid acts to the same amount on the cells
filled in the cryovials. The fluid is stored in a reservoir (5) that
is attached to the aperture and the pressure can be recorded
via a digital manometer (6). The pressure is maintained and
released by several switches (7) in the aperture. Since different
pressure levels showed promising results for inactivation of
tumor cells in earlier studies (7, 10, 21–23), we also first tested
pressure from 100 to 500 MPa at a compression time of 300 s
for some in vitro examinations of the vaccine. According to the
3Rs concept for more ethical use of animals in testing, namely
replacement, reduction and refinement, we focused on whole
tumor cell-based vaccines generated with 200 MPa for the in
vivo tumor models. Generally, after pressurizing, the tumor cells
were first re-cultivated in cell culture flasks (Greiner Bio-one,
Frickenhausen, Germany).
Cell Death Detection by
AnnexinA5/Propidium Iodide Staining
For analyses of cell death forms by flow cytometry (EPICS
XL MCL, Beckman Coulter, Brea, USA), HHP-treated tumor
cells were suspended in 400 µl Ringer (B. Braun, Melsungen,
Germany) and stained with FITC-labeled AnnexinA5 (AnxA5;
0.2 µl, Geneart, life technologies, Regensburg, Germany)
and propidium iodide (PI; 0.4 µl, Sigma Aldrich, Munich,
Germany) according to the protocol of Vermes et al. (24).
AnxA5-negative/PI-negative cells were considered as viable
ones, AnxA5-positive/PI-negative as apoptotic cells and AnxA5-
positive/PI-positive cells as necrotic ones.
Cell Cycle and SubG1 DNA Content
Analyses With Propidium Iodide
1 × 106 tumors cells were fixed in 70 % ethanol and incubated
at −20◦C for at least 20min. Afterwards, a solution containing
Triton X-100 (Sigma Aldrich, Munich, Germany), 200µg/ml
RNase (Biochemica, Buchs, Germany), and 5µg/ml PI was added
at room temperature for at least 30min. The cell cycle phases
were consecutively analyzed by flow cytometry. Apoptotic and
secondary necrotic cells that lost their nuclear DNA content due
to DNA fragmentation show subG1 DNA content (25).
Monitoring of the Clonogenicity of
HHP-Treated Cells in vitro and in vivo
In vitro, the pressurized tumor cells were plated in multiplicates
at increasing concentrations in petri dishes (BD Falcon, New
York, USA) and cultivated for 10 days. After staining the cells
with 3ml methylene blue (Sigma Aldrich, Munich, Germany),
colonies consisting of more than 50 cells were scored (26). For
in vivo analysis, a suspension of 2 × 106 treated tumor cells
in Ringer’s solution was injected subcutaneously into mice. The
subsequent tumor growth was analyzed up to 39 days after
injection of the tumor cells.
Multimodal Treatment of Tumor-Bearing
Mice
All animal experiments were conducted according to the
guidelines of the “Federation of European Laboratory Animal
Science Associations” (FELASA) and the “Gesellschaft für
Versuchstierkunde” (GV-SOLAS) and were authorized by the
government of Mittelfranken/Unterfranken. C57BL/6 mice were
inoculated subcutaneously with 1 × 106 viable B16-F10
melanoma cells. After 8 days, when a visible and vascularized
tumor was established, the mice were either locally irradiated
with 2 × 5Gy at day 8 and 10, subcutaneously vaccinated
next to the tumor with 5 × 106 24 h-aged HHP-treated cells
without any additional adjuvant on day 11, locally irradiated
plus vaccinated, or left untreated. For the induction of CT26
tumors, Balb/c mice were injected subcutaneously with 1.2 ×
106 viable CT26 colon carcinoma cells. In this tumor model,
palpable tumors were established after 14 days. Beginning on
that day, the treatment was conducted in the same scheme as for
the B16-F10 cells. Since pressure of 200 MPa showed promising
results in vitro and in former studies (10, 12, 23) and according
to the 3Rs concept for more ethical use of animals in testing,
this pressure level was used for the in vivo experiments. Tumor
growth was determined with an electronic caliper. The tumor
volume was calculated by the formula VTumor = ½ · (L · B2)
(27). Mice were sacrificed whenever the tumor volume exceeded
1,600 mm3 or the well-being of the mouse was reduced according
to approved criteria. A PRIMART linear accelerator (Siemens,
Munich, Germany) was used for RTx. The local irradiation of
the tumor-bearing mice was performed closely resembling the
clinical situation as previously established and applied by our
group (28, 29).
Immune Phenotyping of Tumors and Blood
Tumor samples and whole blood for immune phenotyping by
multicolor flow cytometry were taken in a group of mice on
day 7 after first irradiation. Erythrocyte lysis of blood samples
was performed with a TQ-PrepTM Workstation (Beckman
Coulter, Brea, USA) prior to the antibody staining. Single
cell suspensions from tumors were obtained with the Tumor
Dissociation Kit and the gentleMACSTM Dissociator according
to the manufacturer’s instructions (Miltenyi Biotec, Bergisch
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Gladbach, Germany). To enrich tumor samples for tumor-
infiltrating leukocytes (TIL), CD45 MicroBeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) for subsequent separation
with MACS R© Technology according to the manufacturer’s
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany)
were used. The following antibodies were applied for the
staining of both, tumor and blood samples: CD3e V450,
CD4 FITC, Ly-6C FITC, CD11c BV510, CD19 APC-Cy7,
and Ly6G PE-Cy7 (all from BD Biosciences, Franklin Lakes,
USA), CD49b APC, PD-1 PE/Dazzle 594, CD8a BV605,
Zombie NIR and Zombie Aqua (all from Biolegend, San
Diego, USA), CD11b APC, CD45.2 PerCP-Cy5.5, MHC-II
(I-A/I-E) eFluor 450 and γδTCR PE (all from eBioscience, San
Diego, USA). All samples were acquired with a CytoFLEX
S flow cytometer (Beckman Coulter, Brea, USA) and
analyzed with the Kaluza software (Beckman Coulter, Brea,
USA). To calculate the concentration of tumor infiltrating
leukocytes (cells/g tumor), tumors were weighed prior
to dissociation.
Statistical Analysis
The types of statistical test for data analyses are depicted in the
figure legends. Results were considered statistically significant for
p < 0.05 (∗) and highly significant for p < 0.01(∗∗).
RESULTS
High Hydrostatic Pressure Treatments at
200 MPa or Higher Pre-dominantly Induce
Necrosis in Tumor Cells
While viability of B16-F10 melanoma cells was hardly affected
by pressurizing with 100 MPa, treatments at 200 MPa or higher
FIGURE 1 | Cell death and clonogenicity of B16-F10 melanoma cells following treatment with HHP. B16-F10 melanoma cells were treated with pressure at 100 MPa
up to 500 MPa for 5min and afterwards cultured for 24 (A,C) and 48 h (B,D), respectively. The cells were either stained with AnxA5-FITC/PI (A,B) or PI in the
presence of detergent (C,D) and cell death as well as cell cycle phases were analyzed by flow cytometry. The percentages of viable (AnxA5−/PI−), apoptotic
(AnxA5+/PI−), and necrotic (AnxA5+/PI+) cells are displayed in (A) and (B). The percentages of cells in the G1-, G2-, and S-phase as well as the subG1 DNA content
are displayed in (C) and (D). Data of three independent experiments are presented as mean ± SD. (E) shows the in vitro colony formation of HHP-treated B16-F10
melanoma cells. Single values, means, and SDs are presented. (F) displays the growth of syngeneic B16-F10 tumors in C57BL/6 mice after subcutaneous injection of
2 × 106 HHP-treated tumor cells. Three mice were used for each treatment condition. Data are presented as mean ± SEM. w/o: mock-treated control. Significant
values are determined by an unpaired, one-tailed Student’s t-test with Welch’s correction for unequal variances; **p < 0.01 related to w/o.
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resulted in mostly necrotic tumor cells. Small percentages of
apoptotic melanoma cells were observed when the tumor cells
were treated with 200 MPa (Figures 1A,B). The latter pressure
already resulted in degraded tumor DNA as early as 24 h after
treatment. Almost all melanoma cells had degraded DNA 2 days
after pressurizing if they were treated with pressure above 100
MPa (Figures 1C,D).
High Hydrostatic Pressure Treatments at
200 MPa or Higher Effectively Inactivate
Tumor Cells
To prove the inactivation of B16-F10 melanoma cells after HHP-
treatment, their potential to form colonies in vitro (Figure 1E)
and their potential for progression in vivo after having
been injected into C57BL/6 mice was analyzed (Figure 1F).
Treatments at 200 MPa or higher completely inhibited the
formation of colonies in vitro. Further, no tumor growth was
seen in vivo after tumor cell injection. Notably, pressure of 100
MPa is not sufficient to suppress colony formation of melanoma
cells. Similar results were already previously observed for CT26
cells (23).
Combination of RTx With Whole Tumor
Cell-Based Vaccine Generated by HHP
Significantly Retards Tumor Growth in
C57BL/6 Mice and Increases Their Survival
Eight and 10 days after tumor inoculation, the tumors were
locally irradiated with 2 × 5Gy and vaccination with HHP-
treated tumor cells was performed at day 11 (Figure 2A).
Vaccination with HHP-treated cells was not sufficient to
significantly slow-down the tumor growth (Figure 2B). At day
21 after tumor inoculation, all mice of the vaccination and
control group had to be euthanized, because the tumor volume
had exceeded 1,600 mm3. RTx resulted in significantly retarded
tumor growth when compared to vaccinated or mock-treated
animals. Vaccination with HHP-treated cells in addition to RTx
at day 11 resulted in further significant tumor growth retardation
and even at day 32 after tumor inoculation three animals could
still be monitored. Similarly to the tumor growth reduction, the
survival of the mice could be significantly improved by RTx
alone, and was further significantly improved when RTx was
combined with vaccination (Figures 2C,D).
Combination of RTx With Whole Tumor
Cell-Based Vaccine Generated by HHP
Generates a Beneficial Immune Cell
Infiltrate for Melanoma
A sole vaccination of the mice with HHP-killed tumor cells
did not affect infiltration of cells of the innate and adaptive
immune system into B16-F10 tumors. RTx with 2 × 5Gy
slightly, but not significantly enhanced the infiltration of NK
cells, monocytes/macrophages, DCs and NKT cells. Only the
combination of RTx with HHP vaccine significantly increased the
total number of immune cells (CD45+) per gram of tumor, which
were almost 3 fold higher compared to mock-treated controls
FIGURE 2 | Impact of radiotherapy and whole tumor cell-based vaccine
generated by HHP on B16-F10 melanoma growth and survival. (A) 1 × 106
viable B16-F10 melanoma cells were injected subcutaneously into syngeneic
C57BL/6 mice. The tumor-bearing mice were either left untreated (mock),
vaccinated at day 11 with 5 × 106 B16-F10 tumor cells that had been
inactivated with 200 MPa (HHP vaccine), locally irradiated at day 8 and 10
after tumor implantation with a single dose of 5Gy per fraction (2 × 5Gy), or
treated with both RTx (2 × 5Gy) and HHP vaccine. The tumor growth is
displayed in (B) and the survival time of C57BL/6 mice after B16-F10 tumor
implantation in (C). When the tumor volume exceeded 1,600 mm3, the mice
were euthanized. The number of mice in the treatment groups, as well as the
results of the Log-Rank (Mantel-Cox) test concerning the survival (C) is
displayed in (D). Significant values are determined by an unpaired, one-tailed
Student’s t-test with Welch’s correction for unequal variances. The normality of
the values was confirmed by a Kolmogorov-Smirnov and Shapiro-Wilk test for
each time point. Four animals of each group were sacrificed on day 15 to
analyze the infiltrating immune cells; *p < 0.05.
(Figure 3A). The immune infiltrates primarily consisted of NK
cells (CD3–, CD49b+; Figure 3B), monocytes or macrophages
(CD11b+, Ly-6C+; Figure 3C) and T cells (CD3+; Figure 3F);
about half of the latter being NKT cells (CD3+, CD49b+;
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FIGURE 3 | Impact of radiotherapy and whole tumor cell-based vaccine generated by HHP on infiltration of immune cells into B16-F10 tumors. Single cell
suspensions of tumors from mice that had been treated with RTx (2 × 5Gy) and/or HHP vaccine (B16-F10 tumor cells that had been inactivated with 200 MPa) were
prepared on day 15 after tumor inoculation. Multicolor flow cytometry was performed to detect tumor-infiltrating immune cell subtypes. The latter were identified as
follows: all immune cells CD45+ (A); natural killer (NK) cells CD49b+, CD3– (B); Monocytes/Macrophages CD11b+, Ly-6C+ (C); dendritic cells (DCs) MHC-II+,
CD11c+ (D); B cells CD19+ (E); total T cells CD3+ (F); NKT cells CD3+, CD49b+ (G); γδT cells CD3+, γδTCR+ (H). Data are presented as box plots showing the
median and minimum to maximum values. n = 4; Mann-Whitney U test was used for statistical analyses compared to the control group; *p < 0.05.
Figure 3G). Although not as prominent and in lower absolute
numbers, also DCs (MHC-II+, CD11c+; Figure 3D) and in
particular γδT cells (CD3+, γδTCR+; Figure 3H) tended to
be present in higher numbers after the combined treatment.
In contrast to the other immune cell types, B cell (CD19+;
Figure 3E) numbers were significantly reduced after RTx plus
vaccination. No major alterations were found for neutrophil,
eosinophil, basophil, and pDC infiltration (data not shown).
For further characterization of the T cell response we
determined the CD4/CD8 composition of the infiltrating T cells
as well as the expression of the immune checkpoint molecule
programmed cell death protein 1 (PD-1). In absolute numbers, T
cells were pre-dominantly CD8+ T cells (Figure 4B). However,
RTx combined with HHP vaccine particularly promoted CD4+
T cell infiltration (Figure 4A). Most tumor-infiltrating CD4+ T
cells expressed PD-1 in response to RTx and combination of RTx
with HHP vaccine enhanced it further significantly (Figure 4C).
In contrast, the majority of tumor-infiltrating CD8+ T cells
expressed PD-1 irrespective of the treatments (Figure 4C). When
focusing on T cells of the peripheral blood of the mice, expression
of PD-1 was observed only in very few CD4+ and CD8+ T cells
(Figure 4D).
Combination of RTx With Whole Tumor
Cell-Based Vaccine Generated by HHP
Induces Retardation of CT26 Tumor Growth
in Balb/c Mice and Increases Their Survival
To investigate if the efficiency of RTx in combination with HHP
vaccination is only a melanoma-specific phenomenon, CT26
colon carcinoma-bearing Balb/c mice were treated similarly as
the B16-F10 melanoma-bearing C57BL/6 mice (Figure 5A). RTx
significantly retarded tumor growth compared to mock-treated
or vaccinated mice. This was also reflected by the prolonged time
until tumors reached a volume of 750 mm3 (Figures 5B–D,F).
The combined treatment with RTx plus vaccination further
delayed tumor growth in about half of the mice (Figure 5E).
In accordance with that, the survival of the mice was further
prolonged (Figures 5G,H).
Compared to B16-F10 tumors, the amount
of tumor-infiltrating CD8+ T cells varied more
(Supplemental Figure 2A), but a trend of reduced tumor
size with higher infiltration of CD8+ T cells was observed
(Supplemental Figure 2B). As seen in the B16-F10 model, most
tumor-infiltrating CD4+ T cells expressed PD-1 in response
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FIGURE 4 | Impact of radiotherapy and whole tumor cell-based vaccine generated by HHP on infiltration of T cells into B16-F10 tumors and on PD-1 expression of T
cells. Single cell suspensions of tumors from mice that had been treated with RTx (2 × 5Gy) and/or HHP vaccine (B16-F10 tumor cells that had been inactivated with
200 MPa) were prepared on day 15 after tumor inoculation. Multicolor flow cytometry was performed to detect tumor infiltrating CD4+ (A) and CD8+ T cells (B),
respectively. Further, expression of PD-1 on T cells being present in the tumors (C) and those circulating in blood (D) is shown. Data are presented as box plots
showing the median and minimum to maximum values. n = 4; Mann-Whitney U test was used for statistical analyses compared to the control group; *p < 0.05.
to RTx, but combination with HHP vaccine did not enhance
it further (Supplemental Figure 2C). Again, the majority of
tumor-infiltrating CD8+ T cells expressed PD-1 irrespective
of the treatment. But in contrast to B16-F10 tumors, RTx
in combination with vaccination further slightly enhanced
PD-1+ CD8+ T cells (Supplemental Figure 2C). As observed
in the B16-F10 model (Figure 4D), only very view CD4+
and CD8+ T cells of the peripheral blood did express PD-1
(Supplemental Figure 2D).
DISCUSSION
Promising results have recently been achieved using
immunotherapy such as checkpoint inhibitors to treat a
range of different tumor entities. However, therapeutic cancer
vaccines as sole immune therapy for solid cancer encounter
three key challenges: immunogenicity of the vaccine, established
diseases burden, and existing immune suppressive tumor
microenvironment (30). Autologous whole tumor cell-based
vaccines have the advantage that target antigens do not have to
be prospectively identified and they deliver many TAAs, which
are however aberrantly expressed self-antigens. In contrast
to neo-antigens, the latter should only be able to activate
remaining low affinity T cells and have to break self-tolerance.
Several additional treatments have been developed and are
discussed to overcome this hurdle, as e.g., repeated vaccination,
addition of adjuvants or co-stimulators (31). Regarding the
latter, RT might come into play. It has been demonstrated that
besides immune suppressive mechanisms, ionizing radiation
has additionally immune stimulatory priorities that enhance
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FIGURE 5 | Impact of radiotherapy and whole tumor cell-based vaccine generated by HHP on CT26 colon carcinoma growth and survival. (A) 1.2 × 106 viable CT26
cells were injected subcutaneously into syngeneic Balb/c mice. The tumor-bearing mice were either left untreated (mock), vaccinated at day 17 with 5 × 106 CT26
tumor cells that had been inactivated with 200 MPa (HHP vaccine), locally irradiated at day 14 and 16 after tumor implantation with a single dose of 5Gy per fraction (2
× 5Gy), or treated with both RTx (2 × 5Gy) and HHP vaccine. The tumor growth is displayed as individual growth curves (B–E) and days until the tumor reached a
volume of 750 mm3 (F). The survival time of Balb/c mice after CT26 tumor implantation is depicted in (G). When the tumor volume exceeded 1,500 mm3, the mice
were euthanized. Significant values are determined by a Kruskal-Wallis test with Dunn’s correction for multiple testing. The number of mice in the treatment groups, as
well as the results of the Log-Rank (Mantel-Cox) test concerning the survival (G) is displayed in (H); *p < 0.05, **p < 0.01.
activation of DCs and improve antigen presentation, both being
pre-requisites for induction of anti-tumor immune responses
(16, 20, 32).
It was already demonstrated for many human cancer
cells lines that HHP treatment with 200 MPa results in
apoptotic and necrotic tumor cells that activate DCs following
their phagocytosis (7, 21). Sipuleucel-T as therapeutic cancer
vaccine against castration-resistant prostate cancer has been
proven to show efficiency (33). This depicts that therapeutic
vaccination with enriched DCs that are stimulated and loaded
with antigen can work. In a pre-clinical setting, just recently
Hradilova et al. demonstrated that HHP-killed lung cancer
cell lines as source of TAAs in combination with the
adjuvants poly(I:C) act as DC maturation signal. They further
showed that DC-based HHP lung cancer vaccine generated
from monocytes of NSCLC patients induces tumor-antigen
specific CD8+ and CD4+ T cells (34). Currently a Phase
I/II clinical trial for NSCLC is ongoing that uses DC-based
active cellular immunotherapy (DCVAC/LuCa) in combination
with chemotherapy and immune enhancers (NCT02470468).
In an orthotopic mouse model of prostate cancer, the same
group demonstrated that DC-based vaccines are as effective as
chemotherapy to retard tumor growth. In this setting, however,
no difference between un-pulsed DCs and those pulsed with
HHP-killed tumor cells was seen. However, a tendency of
increased numbers of CD8+ T cells and NK1.1 cells in the
spleen of the animals was detected when DCs were pulsed with
HHP-killed tumor cells (35).
We have aimed to focus on another cellular vaccine approach
(36) using HHP-killed tumor cells alone as vaccine instead of
tumor cell-loaded DCs. This approach aims to stimulate and
deliver TAAs to DCs in vivo when the vaccine is combined with
local stimulation of the tumor tissue by irradiation. A major
mechanism for the observed synergistic effects is most likely that
HHP-killed tumor cells are phagocytosed by the endogenous DCs
and antigens are presented to T cells for T cell stimulation.
We here show that murine tumor cells, which are necessary to
be applied if consecutive in vivo testing of multimodal therapies
is performed in syngeneic mice (29), are killed in the same way
as human tumor cells (7) by HHP. HHP-treatment was already
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included in the list of immunogenic cell death inducers (37).
We additionally observed that murine tumor cells continue to
degrade DNA following HHP-treatment. This might additionally
impact on the immunogenicity of the vaccine, as it was already
shown for DNA exonuclease Trex1 that it regulates RTx-induced
immunogenicity of tumor cells (38, 39). Therefore, cytosolic
DNA following treatment of the tumor cells with HHP might
contribute via STING-dependent cytosolic DNA sensing to the
immunogenicity of the HHP-vaccine (40). This has however to
be proven in future work.
We focused on the new fact if RTx can be combined with
syngeneic whole tumor cell-based vaccine without previous co-
cultivation of the killed tumor cells with DCs and without
any additional adjuvants. Combining vaccination with therapies
that modify the tumor and its micro-environment should be
promising approaches to enhance the vaccine’s efficacy (41). We
observed significantly reduced tumor growth and significantly
improved survival of B16-F10 tumor-bearing C57BL/6 mice that
had been treated with RTx plus HHP vaccine in comparison to
RTx alone. Just vaccination did not impact on tumor growth and
survival at all. In recent small phase I trials that combine vaccines
with other immunotherapy evidence increases that boosting the
immune system before vaccination can generate a better response
(30). Targeting CTLA-4 in combination with a poxviral-based
vaccine targeting prostate-specific antigen resulted in a small
number of patients with increased frequency of antigen specific
T-cells (42). In another phase I trial for prostate cancer, a vaccine
containing two irradiated prostate cancer cell lines that express
GM-CSF (GVAX-PCa) again in combination with targeting the
immune suppressive immune checkpoint molecule CTLA-4 by
ipilimumab, induced an increased expression of CD40 by DCs.
This again suggests an enhanced DC function in these cancer
patients (43). To exclude that a synergistic effect of RTx and
HHP vaccination is onlymelanoma-specific, we additionally used
the CT26 colon carcinoma model. In accordance with the B16-
F10 tumor model, also CT26 tumor growth was further retarded
when RTx was combined with HHP vaccination. This was seen
in about half (4/9) of the mice.
Since the specific T cell numbers needed for an efficient cancer
vaccine are unknown to date and do vary between tumor type,
antigens and T cell receptor affinity (31), we here focused on
analyses of number and quality of tumor-infiltrating immune
cells following vaccination, RTx and combination of vaccination
and RTx. The immune phenotyping data of B16-F10 tumors
demonstrated an enhanced tumor infiltration of a variety of
immune cells of the innate as well as the adaptive immune
system after combination of RTx and the HHP vaccine. Although
different immune cell subtypes are suspected to have diverse
impact on tumor progression, the infiltration of immune cells is
generally associated with good prognosis for melanoma patients
(44) and for most of the solid tumors (45).
We revealed that combination of RTx with HHP vaccine
generates a favorable anti-tumor immune microenvironment for
melanoma. γδT cells are known to infiltrate into melanoma
and are capable of killing melanoma cells (46). We identified
that only combination of RTx with HHP vaccine increased
the number of γδT cells in the tumor. Further, NK cells
were significantly enhanced. These innate immune cells are
key players in mediating anti-tumor immunity (47). We also
previously observed that NK cell depletion after immunization
results in a significant acceleration of melanoma growth (48).
NKT cells were also significantly enhanced and may lead to
downstream activation of both innate and adaptive immune
cells in the tumor microenvironment (49). Since B cells
might foster tumor-promoting humoral immunity in melanoma
(50), decreased numbers following RTx plus HHP vaccine
treatment should also contribute to a beneficial therapy-induced
tumor microenvironment.
They et al. demonstrated that a favorable modulation of the
melanoma microenvironment fosters the infiltration of CD4+
and CD8+ T cells (51). However, tumor escape by upregulation
of PD-1 is frequent and additional treatment with anti-PD-
1 antibody restored effector functions of CD4+ and CD8+ T
cells as well as of NK cells and γδT cells. We demonstrate that
combination of RTx with HHP vaccine also fosters infiltration
of CD4+ and CD8+ T cells as well as that of NK cells and γδT
cells into B16-F10 melanomas. In the CT26 model, combination
of RTx plus HHP vaccine resulted in heterogeneously responding
tumors. Here, high CD8+ T cell infiltration tended to result in
smaller tumors (Supplemental Figure 2). We further observed a
high expression of PD-1 on infiltrating T cells. This depicts both
that activation of the T cells against the tumor has taken place
and that subsequently immune suppressive checkpoint molecules
such as PD-1 are expressed to regulate the immune response and
that re-stimulation of the immune system by anti-PD-1 treatment
will be necessary. Dyck et al. demonstrated in the CT26 model
that anti-PD-1 treatment reduced regulatory T cell induction
and enhanced CD8+ T cell mediated tumor killing. Combined
treatment of tumor-bearing mice with a vaccine, comprising
heat-shocked irradiated tumor cells and a TLR 7/8 agonist,
significantly reduced tumor growth and enhanced survival (52).
This calls for further improvement of induction of anti-tumor
immune responses by combining RTx plus HHP vaccine with
immune checkpoint-inhibition in the future (16, 18, 53). While
almost absent in blood, the majority of CD8+ T cells infiltrating
into B16 tumors and almost all CD8+ T cells in CT26 tumors
expressed PD-1. This enrichment of PD-1+ T cells in the tumor
was already reported for patients with metastatic disease (54),
indicating that the up-regulation of the inhibitory receptor PD-
1 is driven by the tumor microenvironment. Nevertheless, PD-1
expression can also be considered as favorable marker for an
effectively primed T cell response, as suggested by Fernandez-
Poma et al. Only the fraction of T cells selected for positive
PD-1 expression exhibited anti-tumor reactivity when adoptively
transferred into mice and combination with anti-PD-L1 further
enhanced tumor control (55).
Future work will focus on a triple combination of RTx with
HHP vaccination and checkpoint inhibition for the induction
of anti-tumor immune responses to primary and abscopal
tumors (16). Furthermore, one should think about to modify the
radiation dose that has most likely to be adapted very individually
in the future for optimization of immune stimulation by RTx.
However, one has to be aware that too high single dose might
again decrease immunogenicity of the tumors (38). Additionally,
the HHP-vaccine could be injected multiple times to break
self-tolerance with appropriate adjuvants. We demonstrated in
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another pre-clinical setting that repeated vaccination of tumor
cells that had been killed by RTx in combination with heat is
superior to single vaccination with regard to induction of tumor
growth retardation (48). Even though many hurdles still will
have to be overcome for most beneficial combination of RTx
with tumor cell-based vaccines, such approaches are particularly
important for patients who harbor weak spontaneous immune
responses to their cancer. Furthermore, development of cancers
vaccines have to respect that standard of care for most cancer
patients involves chemotherapy and/or RTx (31). The here
presented pre-clinical work give first hints that RTx is well-
combinable with tumor-cell based vaccines generated by HHP
and provides a basis for continuing work on optimization of
multimodal cancer therapies.
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Supplemental Figure 1 | Technical sketch of the high hydrostatic pressure
aperture that was used for the generation of the tumor cell-based vaccine. The
numbered properties of the aperture are explained in the main text.
Supplemental Figure 2 | Impact of radiotherapy and HHP vaccination on
infiltration of T cells into CT26 tumors and on PD-1 expression of T cells. Single
cell suspensions of tumors from mice that had been treated with RTx (2 × 5Gy)
and/or HHP vaccine (CT26 tumor cells that had been inactivated with 200 MPa)
were prepared on day 21 after tumor inoculation. Multicolor flow cytometry was
performed to detect tumor infiltrating CD4+ and CD8+ T cells (A). The infiltration
of CD8+ T cells into the tumor in relation to the tumor weight is depicted in (B).
Further, expression of PD-1 on CD4+ and CD8+ T cells being present in the
tumors (C) and those circulating in blood (D) is shown. Data are presented as box
plots showing the median and minimum to maximum values. n = 6;
Mann-Whitney U test was used for statistical analyses; ∗p < 0.05.
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